Lumida
/EDIT
⌘K
Editas Medicine Inc

Editas Medicine Inc

EDIT
$2.70USD+1.89%+0.05 today

MARKET CAP

414.7M

P/E (TTM)

FWD P/E

DAY RANGE

$3 – $3

52W RANGE

$2
$5

AI Summary

Stalk
StalkMedium

While the asset remains in a Stage 4 decline with a decisive support failure and lower-high/lower-low regime, mean-reversion conditions are present as near‐low forward P/E, elevated FCF yield, and price at a prior defended zone signal a potential counter‐trend opportunity. Short-term price is extended below declining EMAs without clear exhaustion, suggesting deferred entry. Execution should focus on stalking shallow pullbacks into the 9 EMA, 21 EMA, or the area just above the 200 DMA to participate in an anticipated mean-reversion.

  • Renicel Ruby trial: all patients free from vaso-occlusive events post-infusion.
  • Q2 2024 cash of $318M funds operations and R&D into 2026.
  • Q1 2024 revenue dropped to $1.1M versus $9.9M in Q1 2023.
Full analysis →
Sales, Adj.
Gross Profit, Adj.
EBITDA, Adj.
EBIT
Net Income